Search results
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
Zacks via Yahoo Finance· 23 hours agoArexvy had an exceptional launch and generated £1.2 billion...time, GSK expects Arexvy to generate...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 4 days agoPfizer is competing against GSK's Arexvy, which hit the market about the same time in 2023. Moderna...
FDA approves first RSV vaccine for at-risk adults in their 50s
CBS News· 4 days agoThe Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus...
FDA gives nod to RSV vaccine for people in their 50s
Medical Xpress· 17 hours agoDrugmaker GSK's Arexvy vaccine, as well as vaccines from Pfizer and Moderna, are already approved for use in adults 60 and older, since age brings higher...
Adults 60+ Will Have 3 RSV Vaccines to Choose From This Year
Verywell Health via Yahoo News· 6 days agoThe FDA approved mRESVIA based on data from a clinical trial that included more than 35,000 adults...
Moderna says combo COVID-flu vaccine showing promising results — and more
WGN Chicago via Yahoo News· 14 hours agoModerna plans to file for federal approval this summer and hopes to have the vaccine available next...
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
Reuters via Yahoo News· 4 days agoThe shot, branded Arexvy, and vaccines from rivals Pfizer and Moderna are already approved for...
FDA clears GSK's RSV vaccine for adults ages 50-59
United Press International via Yahoo News· 3 days agoThe U.S. Food and Drug Administration on Friday approved GSK's respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the...
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
CNBC· 4 days agoThe shot, called Arexvy, is the first vaccine cleared by the FDA to protect that population from...
FDA panel recommends new COVID-19 vaccine formula for fall
UPI· 5 days agoDr. Peter Marks, who oversees the FDA's vaccine division, urged the committee to consider...